Magenballonimplantation – eine Bestandsaufnahme unter
                    Berücksichtigung eigener Erfahrungen

Rebecca Keßler; Anne Glitsch; Björn Hübner; Simone Gärtner; Antje Steveling; Maciej Patrzyk; Wolfram Keßler

doi:10.1055/a-2185-7671

Adipositas - Ursachen, Folgeerkrankungen, Therapie, Table of Contents

Adipositas - Ursachen, Folgeerkrankungen, Therapie 2023; 17(04): 210-214
DOI: 10.1055/a-2185-7671

Review

Magenballonimplantation – eine Bestandsaufnahme unter Berücksichtigung eigener Erfahrungen

Gastric Balloon Implantation – A Review Taking Into Account Own Experiences

Authors

Rebecca Keßler

¹Institut für diagnostische Radiologie und Neuroradiologie, Universitätsmedizin Greifswald, Greifswald, Deutschland
Anne Glitsch

²Klinik und Poliklinik für Allgemeine Chirurgie, Viszeral-, Thorax- und Gefäßchirurgie, Universitätsmedizin Greifswald, Greifswald, Deutschland
Björn Hübner

³Klinik und Poliklinik für Mund-, Kiefer- und Gesichtschirurgie, Universitätsmedizin Greifswald, Greifswald, Deutschland
Simone Gärtner

⁴Klinik und Poliklinik für Gastroenterologie, Endokrinologie, Nephrologie, Rheumatologie und Ernährungsmedizin, Universitätsmedizin Greifswald, Greifswald, Deutschland
Antje Steveling

⁴Klinik und Poliklinik für Gastroenterologie, Endokrinologie, Nephrologie, Rheumatologie und Ernährungsmedizin, Universitätsmedizin Greifswald, Greifswald, Deutschland
Maciej Patrzyk

²Klinik und Poliklinik für Allgemeine Chirurgie, Viszeral-, Thorax- und Gefäßchirurgie, Universitätsmedizin Greifswald, Greifswald, Deutschland
Wolfram Keßler

²Klinik und Poliklinik für Allgemeine Chirurgie, Viszeral-, Thorax- und Gefäßchirurgie, Universitätsmedizin Greifswald, Greifswald, Deutschland

Abstract

Zusammenfassung

Die Magenballontherapie wird aktuell konträr diskutiert. Dennoch stellt dieses Verfahren aus unserer Sicht ein bewährtes und verhältnismäßig sicheres Hilfsmittel zur kontrollierten Gewichtsreduktion dar. Die hier nachgewiesene Reduktion aller Körperfettkompartimente und die signifikante Reduktion des Lebervolumens ist ein Ergebnis, welches weitere Forschungsansätze eröffnet und in der Folge ggf. auch eine (positive) Neubewertung des Magenballons im Rahmen der Adipositas-Therapie erfordert. So ist über das Verhalten von Gasblasen in Magenballons bisher wenig bekannt. Bei der zukünftigen Forschung sollte jedoch sehr viel Wert auf eine korrekte Indikationsstellung (Ziel der Magenballontherapie) und Durchführung der Implantation gelegt werden.

Abstract

Gastric balloon therapy is currently discussed in a controverse manner. From our point of view, the technique is well established and allows an overall safe approach to induce weight loss under controlled conditions. We observed a reduction in all body fat compartments and a significant reduction in liver volume. These results should be substantiated by future studies and if these are successful, the judgment on gastric balloon therapy for obesity therapy may be changed to a more favourable opinion. For example, little is known about the behavior of gas bubbles within the balloon. For any future research, the correct conclusion on the indication (what is the goal of implanting the gastric balloon?), and the best technical performance during implantation are of outmost importance.

Schlüsselwörter

Magenballon - Adipositas - Lebervolumen - sarcopen Adipositas - Fettgewebe

Key Words

gastric balloon - obesity - liver volume - sarcopenic adiposity - adipose tissue

Full Text

References

Literatur
1 Lari E, Burhamah W, Lari A. et al. Intra-gastric balloons – The past, present and future. Ann Medicine Surg 2021; 63: 102138
2 Mechanick JI, Apovian C, Brethauer S. et al. Clinical Practice Guidelines for the perioperative Nutrition, Metabolic, and nonsurgical Support of Patients undergoing bariatric Procedures – 2019 Update: cosponsered by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic C & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesioligists-Executive Summary*. Endocr Pract 2019; 25: 1-75
3 FDA. The FDA alerts health care providers about potential risks with liquid-filled intragastric balloons | FDA [Internet]. 2017 [cited 2021 Jul 11]. Available from: https://www.fda.gov/medical-devices/letters-health-care-providers/fda-alerts-health-care-providers-about-potential-risks-liquid-filled-intragastric-balloons
4 Mathus-Vliegen E, Alders P, Chuttani R. et al. Outcomes of intragastric balloon placements in a private practice setting. Endoscopy 2014; 47
5 Dayyeh BKA, Kumar N, Edmundowicz SA. et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc 2015; 82: 425-438.e5
6 Stavrou G, Tsaousi G, Kotzampassi K. Life-threatening visceral complications after intragastric balloon insertion: Is the device, the patient or the doctor to blame?. Endosc Int Open 2019; 07: E122-E129
7 Fernandes JFAM CarvalhoGL, Lima DL. et al. Intragastric Balloon for Overweight Patients. Jsls J Soc Laparoendosc Surg 2016; 20: e2015.00107
8 Dastis N, François E, Deviere J. et al. Intragastric Balloon for Weight Loss: Results in 100 Individuals Followed for at least 2.5 Years. Endoscopy 2009; 41: 575-580
9 Zerrweck C, Maunoury V, Caiazzo R. et al. Preoperative Weight Loss with Intragastric Balloon Decreases the Risk of Significant Adverse Outcomes of Laparoscopic Gastric Bypass in Super-Super Obese Patients. Obes Surg 2012; 22: 777-782
10 Dabrowiecki S, Szczesny W, Poplawski C. et al. Intragastric Balloon (BIB System) in the Treatment of Obesity and Preparation of Patients for Surgery – Own Experience and Literature Review. Pol J Surg 2011; 83: 181-187
11 Göttig S, Daskalakis M, Weiner S. et al. Analysis of Safety and Efficacy of Intragastric Balloon in Extremely Obese Patients. Obes Surg 2009; 19: 677-683
12 Choudhary NS, Puri R, Saraf N. et al. Intragastric balloon as a novel modality for weight loss in patients with cirrhosis and morbid obesity awaiting liver transplantation. Indian J Gastroenterology 2016; 35: 113-116
13 AWMF. https://www.awmf.org/uploads/tx_szleitlinien/088-001l_S3_Chirurgie-Adipositas-metabolische-Erkrankugen_2018-02.pdf">https://www.awmf.org/uploads/tx_szleitlinien/088-001l_S3_Chirurgie-Adipositas-metabolische-Erkrankugen_2018-02.pdf [Internet]. S3-Leitlinie: Chirurgie der Adipositas und metabolischer Erkrankungen. 2018 [cited 2021 Jul 9]. Available from: https://www.awmf.org/uploads/tx_szleitlinien/088-001l_S3_Chirurgie-Adipositas-metabolische-Erkrankugen_2018-02.pdf
14 Gottig S, Daskalakis M, Weiner S. et al. Analysis of safety and efficacy of intragastric balloon in extremely obese patients. Obes Surg 2009; 19: 677-683
15 Yorke E, Switzer NJ, Reso A. et al. Intragastric Balloon for Management of Severe Obesity: a Systematic Review. Obesity surgery 2016; 26: 2248-2254
16 Ball W, Raza SS, Loy J. et al. Effectiveness of Intra-Gastric Balloon as a Bridge to Definitive Surgery in the Super Obese. Obes Surg 2019; 29: 1932-1936
17 Reece LJ, Sachdev P, Copeland RJ. et al. Intra-gastric balloon as an adjunct to lifestyle support in severely obese adolescents; impact on weight, physical activity, cardiorespiratory fitness and psychosocial well-being. International journal of obesity 2005; 2017: 591-597
18 Barrichello S, Badurdeen D, Hedjoudje A. et al. The Effect of the Intra-gastric Balloon on Gastric Emptying and the DeMeester Score. Obes Surg 2020; 30: 38-45
19 Nikolic M, Boban M, Ljubicic N. et al. Morbidly obese are ghrelin and leptin hyporesponders with lesser intragastric balloon treatment efficiency: ghrelin and leptin changes in relation to obesity treatment. Obesity surgery 2011; 21: 1597-1604
20 Herve J, Wahlen CH, Schaeken A. et al. What Becomes of Patients One Year after the Intragastric Balloon has been Removed?. Obes Surg 2005; 15: 864-870
21 Singh S, de Moura DTH, Khan A. et al. Intragastric Balloon Versus Endoscopic Sleeve Gastroplasty for the Treatment of Obesity: a Systematic Review and Meta-analysis. Obes Surg 2020; 30: 3010-3029
22 Ienca R, Jarallah MA, Caballero A. et al. The Procedureless Elipse Gastric Balloon Program: Multicenter Experience in 1770 Consecutive Patients. Obes Surg. 2020 30. 3354-3362
23 Lehmann S, Linder N, Retschlag U. et al. MRI assessment of changes in adipose tissue parameters after bariatric surgery. Plos One 2018; 13: e0206735
24 Vogt LJ, Steveling A, Meffert PJ. et al. Magnetic Resonance Imaging of Changes in Abdominal Compartments in Obese Diabetics during a Low-Calorie Weight-Loss Program. Plos One 2016; 11: e0153595
25 Barazzoni R, Bischoff S, Boirie Y. et al. Sarcopenic Obesity: Time to Meet the Challenge. Obesity Facts 2018; 11: 294-305
26 Keßler R, Glitsch A, Hübner B. et al. Abdominal Morphologic Changes in MRI during Gastric Balloon Therapy. Obes Facts 2022; 15: 703-710
27 Takihata M, Nakamura A, Aoki K. et al. Comparison of intragastric balloon therapy and intensive lifestyle modification therapy with respect to weight reduction and abdominal fat distribution in super-obese Japanese patients. Obes Res Clin Pract 2013; 8: e331-e338
28 Wu F-Z, Huang Y-L, Wu CC. et al. Differential Effects of Bariatric Surgery Versus Exercise on Excessive Visceral Fat Deposits. Medicine 2016; 95: e2616
29 Merlotti C, Ceriani V, Morabito A. et al. Subcutaneous fat loss is greater than visceral fat loss with diet and exercise, weight-loss promoting drugs and bariatric surgery: a critical review and meta-analysis. Int J Obes 2005 2017; 41: 672-682
30 Frutos MD, Morales MD, Lujan J. et al. Intragastric balloon reduces liver volume in super-obese patients, facilitating subsequent laparoscopic gastric bypass. Obes Surg 2007; 17: 150-154
31 Vaurs C, Diméglio C, Charras L. et al. Determinants of changes in muscle mass after bariatric surgery. Diabetes Metab 2015; 41: 416-421
32 Cava E, Yeat NC, Mittendorfer B. Preserving Healthy Muscle during Weight Loss. Adv Nutrition Bethesda Md 2017; 8: 511-519
33 Thibault R, Huber O, Azagury DE. et al. Twelve key nutritional issues in bariatric surgery. Clin Nutr 2016; 35: 12-17
34 Gore N, Ravindran P, Chan DL. et al. Pancreatitis from intra-gastric balloon insertion: Case report and literature review. Int J Surg Case Reports 2018; 45: 79-82
35 Said F, Robert S, Mansour EK. Pancreatitis and intragastric balloon insertion. Surg Obes Relat Dis Official J Am Soc Bariatr Surg 2015; 12: e33-e34
36 Albanopoulos K, Natoudi M, Sioka E. et al. Gastritis might be considered as a technical factor affecting laparoscopic sleeve gastrectomy. J Surg Case Reports 2018; 2018 rjy169
37 Mojkowska A, Gazdzinski S, Fraczek M. et al. Gastric Ulcer Hemorrhage – a Potential Life-Threatening Complication of Intragastric Balloon Treatment of Obesity. Obesity Facts 2017; 10: 153-159
38 Tate CM, Geliebter A. Intragastric Balloon Treatment for Obesity: FDA Safety Updates. Adv Ther 2017; 35: 1-4
39 Genco A, Bruni T, Doldi SB. et al. BioEnterics Intragastric Balloon: The Italian Experience with 2,515 Patients. Obes Surg 2005; 15: 1161-1164
40 Stavrou G, Tsaousi G, Kotzampassi K. Life-threatening visceral complications after intragastric balloon insertion: Is the device, the patient or the doctor to blame?. Endosc Int Open 2019; 7: E122-E129
41 FDA. UPDATE: Potential Risks with Liquid-filled Intragastric Balloons – Letter to Health Care Providers | FDA. 2020Available from: https://www.fda.gov/medical-devices/letters-health-care-providers/update-potential-risks-liquid-filled-intragastric-balloons-letter-health-care-providers-1
42 Schienkiewitz A, Mensink GBM, Scheidt-Nave C. Comorbidity of overweight and obesity in a nationally representative sample of German adults aged 18-79 years. Bmc Public Health 2012; 12: 658
43 Jaacks LM, Vandevijvere S, Pan A. et al. The obesity transition: stages of the global epidemic. The lancet Diabetes & endocrinology 2019; 7: 231-240
44 Prentice AM. The emerging epidemic of obesity in developing countries. Int J Epidemiol 2006; 35: 93-99